PFM Health Sciences, LP
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$936.4M2026 Q3+ $66.3M options (notional, not included)
Positions84
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.34.2%
What Changed This Quarter?
Top Holdings
ASND
Ascendis Pharma A/S
5.2%
AXSM
Axsome Therapeutics
4.1%
XBIPUT
SPDR Series
3.8%
UTHR
United Therapeutics
3.7%
THC
Tenet Healthcare
3.2%
INBX
Inhibrx Biosciences
3.2%
LLY
Eli Lilly
2.9%
NBIX
Neurocrine Biosciences
2.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.